StockNews.com Downgrades Teva Pharmaceutical Industries (NYSE:TEVA) to Buy

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was downgraded by stock analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Wednesday.

TEVA has been the subject of several other reports. UBS Group increased their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, October 21st. Finally, Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $20.00.

Teva Pharmaceutical Industries Stock Up 1.5 %

Shares of Teva Pharmaceutical Industries stock traded up $0.32 during trading on Wednesday, reaching $21.20. The stock had a trading volume of 23,678,977 shares, compared to its average volume of 9,410,627. The company has a market capitalization of $24.02 billion, a price-to-earnings ratio of -24.94, a P/E/G ratio of 0.99 and a beta of 0.79. The stock has a fifty day moving average price of $17.54 and a two-hundred day moving average price of $17.43. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries has a 52 week low of $10.13 and a 52 week high of $21.98.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the firm's stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.55% of the company's stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. Sanctuary Advisors LLC grew its position in Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after acquiring an additional 664 shares during the last quarter. Sequoia Financial Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries by 0.7% in the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company's stock valued at $2,025,000 after buying an additional 805 shares during the period. DGS Capital Management LLC raised its holdings in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after buying an additional 872 shares during the last quarter. Smithfield Trust Co increased its position in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after acquiring an additional 980 shares during the period. Finally, Signaturefd LLC raised its stake in shares of Teva Pharmaceutical Industries by 16.9% during the third quarter. Signaturefd LLC now owns 7,583 shares of the company's stock valued at $137,000 after acquiring an additional 1,094 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.